Plain-English translation of NCT06346912 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing CD19-BAFF CAR-T cell therapy, a new treatment that uses your own immune cells to fight blood cancers. Researchers have already confirmed that this treatment is safe in earlier studies, and now they want to understand how well it works and gather more information about long-term safety in patients whose cancer has come back or stopped responding to standard chemotherapy.
Patients with relapsed or refractory B-cell acute lymphoblastic leukemia and non-Hodgkin lymphoma have very limited options when their cancer no longer responds to standard treatments. This trial exists to see whether this new cell-based therapy can offer hope to patients who have exhausted conventional options.
You likely qualify if…
You likely don't qualify if…
You would receive the new cell therapy through an infusion, with the dose increasing gradually as the study progresses. The study will monitor you closely to watch for side effects and to see how well the treatment works at fighting your cancer. Researchers will track your health over time and collect information about any delayed or rare complications that might occur.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
Zhejiang University
Collaborators
Yake Biotechnology Ltd.
Enrollment target
~20 participants
Started
May 2024
Primary completion
May 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in May 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
He Huang, MD
Zhejiang University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.